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Antimicrobial Peptides: Effector Substances of
Innate Immunity
From the outside and within, we are constantly bombarded with
a myriad of diverse microbial species. However, our bodies are
equipped with an evolutionarily conserved innate immune defense
system that allows us to thwart potential pathogens. Antimicrobial
peptides (AMPs) are a unique and assorted group of molecules
produced by living organisms of all types, considered to be part of
the host innate immunity [1,2]. These peptides demonstrate
potent antimicrobial activity and are rapidly mobilized to
neutralize a broad range of microbes, including viruses, bacteria,
protozoa, and fungi [3]. More significantly, the ability of these
natural molecules to kill multidrug-resistant microorganisms has
gained them considerable attention and clinical interest [1]. With
the growing microbial resistance to conventional antimicrobial
agents, the need for unconventional therapeutic options has
become urgent. This article provides an overview of AMPs, their
biological functions, mechanism of action, and applicability as
alternative therapeutic agents.
Structure and Classification
Antimicrobial peptides are small, positively charged, amphi-
pathic molecules (which possess both hydrophobic and hydrophilic
regions) of variable amino acid composition and length (six to 100
amino acids). Based on their secondary structure, AMPs are
grouped into four major classes: b-sheet, a-helical, loop, and
extended peptides (Figure 1) [1]. Currently, more than 800 natural
AMPs with several different sequences have been isolated from a
wide range of organisms (Antimicrobial Peptide Database, http://
aps.unmc.edu/AP/main.php). In humans, the most prominent
innate AMPs are the cathelicidins and defensins produced
primarily by cells of the immune system and the histatins
produced and secreted into the saliva by the parotid, mandibular,
and submandibular salivary glands [4–6].
Mechanism of Antimicrobial Activity
Despite their vast diversity, most AMPs work directly against
microbes through a mechanism involving membrane disruption
and pore formation, allowing efflux of essential ions and nutrients.
The molecular mechanism and pathway of membrane permeation
may vary for different peptides depending on a number of
parameters, such as the amino acid sequence, membrane lipid
composition, and peptide concentration [3]. Although the mech-
anisms by which peptides associate with and permeabilize microbial
cellmembranesarenot entirelyclear,AMPsareproposedtobindto
thecytoplasmicmembrane,creatingmicelle-likeaggregates,leading
to a disruptive effect (Figure 2). However, a mounting body of
evidence indicates the presence of additional or complementary
mechanisms such as intracellular targeting of cytoplasmic compo-
nentscrucial topropercellularphysiology (Figure 2)[7,8]. Thus, the
initial interaction between the peptides and the microbial cell
membrane would allow them to penetrate into the cell to bind
intracellular molecules, resulting in the inhibition of cell wall
biosynthesis and DNA, RNA, and protein synthesis. AMPs also
possess anti-viral properties, inhibiting viral fusion and egress, thus
preventing infection and viral spread via direct interactions with the
membranous viral envelope and host cell surface molecules. These
properties, combined with the broad range of activity and the short
contacttime required to inducekilling, haveled to the consideration
of AMPs as excellent candidates for development as novel
therapeutic agents. Therefore, insights into the mechanisms
employed by AMPs will facilitate new approaches to discover and
develop pharmacologic agents.
Therapeutic Potential
An essential requirement for any antimicrobial agent is that it
has selective toxicity for the microbial target, which is an
important feature of AMPs, as their preferential interaction with
microbial cells makes them non-toxic to mammalian cells. Based
on the significant distinctions between mammalian and microbial
cells, several factors determine the selectivity of AMPs, such as
membrane composition, transmembrane potential, polarization,
and structural features [7–9]. AMPs have a number of potential
advantages as future therapeutics; in addition to their broad
spectrum antimicrobial activity and rapid killing of microbes, they
neutralize endotoxin and are unaffected by classical antibiotic
resistance mechanisms [7,9,10]. Significantly, given their proclivity
to permeabilize target microbial membranes, the most promising
potential application for AMPs is for enhancement of the potency
of existing antimicrobials by facilitating access into the microbial
cell, resulting in synergistic therapeutic effects [8,11]. Moreover,
unlike conventional antibiotics, which microbes readily circum-
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likely due to the profound changes in membrane structure
warranted to confer the microbial cell with resistance. Interest-
ingly, although the fundamental biological role of AMPs is
antimicrobial activity, recent studies have highlighted novel
alternative functions for these molecules, including immunomod-
ulatory activities, neutralization of endotoxins, wound healing, and
anti-neoplastic properties [12–16]. Based on the broad and diverse
biological functions of these endogenous peptides, AMPs currently
are being widely used as blueprints for the development of
innovative therapeutic agents that may be used as antimicrobials,
modifiers of inflammation, or in cancer therapy.
Hurdles: Resistance and Immune Evasion
There are several barriers that might impede the development
of AMPs as commercial therapeutic agents or restrict their
applicability. Among the potential impediments are the high
production costs and susceptibility to proteolytic degradation,
although AMPs are amenable to extensive chemical modification,
Figure 1. Protein models representing the structural differences of the four classes of antimicrobial peptides. Antimicrobial peptides
can be grouped into four major classes based on their secondary structures, including the (A) a-helical peptides, (B) peptides composed of a series of
b-sheets, (C) peptides that adopt unconventional structures, such as extended helices, and (D) peptides that assemble into loops. All structures were
obtained freely from the RCSB Protein Data Bank (PDB) (http://www.pdb.org/) and have been referenced according to their Digital Object Identifier
(DOI) [23]. Additional information for each AMP may be obtained by consulting the RCSB PDB and cross-referencing the DOI.
doi:10.1371/journal.ppat.1001067.g001
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microbial drug resistance becoming a global public health
problem, it has become imperative that new antimicrobials
combat the increasing rise in resistance. The development of
microbial resistance against AMPs is rare [10]. Nevertheless,
microbial pathogens have the capabilities to coordinate counter-
measures to circumvent antimicrobial peptide targeting and evade
host immune defenses [8,17,18].
The newly identified mechanism of immune evasion employed
by the pathogenic fungal species Candida albicans, the etiologic
agent of oral candidiasis (thrush), serves as a good example of
microbial strategies to thwart the deleterious effects of AMPs [5].
The salivary antimicrobial peptide histatin-5 exhibits potent anti-
candidal properties and therefore is considered to be important in
protecting the oral cavity against candidiasis. However, recently C.
albicans was described to be capable of cleaving histatin-5 not only
at specific amino acid residues required for successful intracellular
uptake of histatin-5, but also at sites located within the
antimicrobial fragment of histatin-5, resulting in deactivation of
its anti-candidal potency [19]. This proteolytic ability was
attributed to a family of proteolytic enzymes produced by C.
albicans, the secreted aspartyl proteases, responsible for host tissue
degradation and invasion by the fungus [20]. The outcome of this
host–pathogen interaction in terms of clinical manifestation was
demonstrated to be subject to the ratio of histatin-5 in the saliva to
C. albicans cell density in the oral cavity [19]. Although C. albicans is
innately sensitive to histatin-5, compensatory up-regulation of
proteolytic enzymes would constitute a potential mechanism for
the pathogen to evade host innate defenses [19,20]. Similarly, the
yeast Candida glabrata appears to be unaffected by concentrations of
AMPs due to increased baseline expression of drug efflux pumps
[21].
While acquired resistance to AMPs is less likely to occur as
compared to the traditional antimicrobial therapies, some gram-
negative bacteria have evolved to utilize various cellular enzymes
to biochemically modify and reduce the net negative charge of
their cell membranes. By making the net charge more positive,
static repulsive forces antagonize insertion of positively charged
AMPs into the bacterial membrane [22]. Several other strategies
have been described that can result in decreased susceptibility of
bacteria to AMPs, such as secretion of inactivating proteins or
exportation via efflux pumps. Therefore, we cannot exclude the
fact that resistance may evolve if microbial populations are
consistently exposed to AMPs. Nevertheless, future research aimed
at broadening our understanding of the mechanisms used by both
host and microbe will undoubtedly lead to new therapeutic options
for managing resistant microbial infections.
Conclusion
Presently, AMPs represent one of the most promising future
strategies for combating infections and microbial drug resistance.
This is evident by the increasing number of studies to which these
peptides are subjected. As our need for new antimicrobials
becomes more pressing, the question remains: can we develop
novel drugs based on the design principles of primitive molecules?
Figure 2. The proposed diverse mechanistic modes of action for antimicrobial peptides in microbial cells. (A) Disruption of cell
membrane integrity: (1) random insertion into the membrane, (2) alignment of hydrophobic sequences, and (3) removal of membrane sections and
formation of pores. (B) Inhibition of DNA synthesis. (C) Blocking of RNA synthesis. (D) Inhibition of enzymes necessary for linking of cell wall structural
proteins. (E) Inhibition of ribosomal function and protein synthesis. (F) Blocking of chaperone proteins necessary for proper folding of proteins. (G)
Targeting of mitochondria: (1) inhibition of cellular respiration and induction of ROS formation and (2) disruption of mitochondrial cell membrane
integrity and efflux of ATP and NADH.
doi:10.1371/journal.ppat.1001067.g002
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